WCM App for Cancer Survivors
Recruiting in Palo Alto (17 mi)
Age: 18+
Sex: Any
Travel: May Be Covered
Time Reimbursement: Varies
Trial Phase: Academic
Recruiting
Sponsor: University of Illinois at Chicago
Disqualifiers: Active treatment, No cancer diagnosis, others
No Placebo Group
Trial Summary
What is the purpose of this trial?Examine the Feasibility, Acceptability, User Satisfaction, and Response Patterns and Preliminary Efficacy on Targeted Patient Reported Outcomes. Using a pre-post, single arm feasibility design with cancer survivors with disabilities
Will I have to stop taking my current medications?
The trial does not specify whether you need to stop taking your current medications. However, it mentions that participants may still be undergoing endocrine or hormone therapies, suggesting that some medications might be allowed.
What data supports the effectiveness of the WCM app treatment for cancer survivors?
Research shows that smartphone apps can help cancer survivors by improving their quality of life and supporting their care after treatment. Similar apps have been used to help patients stick to their treatment plans and manage their health better, which suggests that the WCM app could be effective in supporting cancer survivors.
12345Is the WCM App safe for cancer survivors?
Research on similar apps shows they are generally safe and help manage side effects during cancer treatment. For example, a study using a similar app for chemotherapy patients found it reduced side effects, and another app for radiation therapy patients received positive feedback for its safety and communication features.
13678How is the WCM app treatment different from other treatments for cancer survivors?
The WCM app is unique because it is an eHealth self-management tool that helps cancer survivors independently manage their health by providing personalized feedback and guidance on supportive care options, unlike traditional treatments that often require direct healthcare provider involvement.
49101112Eligibility Criteria
This trial is for cancer survivors aged 18 or older who have finished active treatment for breast cancer, head and neck cancer, or sarcoma. Participants must self-identify as having disabling after-effects of cancer per the Americans with Disabilities Act, be medically stable to engage in two data collection sessions totaling 2 hours, and communicate in English.Inclusion Criteria
You consider yourself to have a disability as defined by the Americans with Disabilities Act and the American Community Survey's 6 disability questions.
I consider myself disabled due to cancer or its treatment.
This criterion refers to the process of testing the high-quality version of the WeCanManage prototype to see how easy and practical it is to use.
+7 more
Trial Timeline
Screening
Participants are screened for eligibility to participate in the trial
2-4 weeks
Treatment
Participants use the WeCanManage app for self-management intervention
8 weeks
Baseline evaluation, completion evaluation, and 4-week post-completion evaluation
Follow-up
Participants are monitored for safety and effectiveness after treatment
4 weeks
Participant Groups
The WeCanManage (WCM) app is being tested for its feasibility, acceptability, user satisfaction, response patterns and preliminary efficacy on patient-reported outcomes among cancer survivors with disabilities using a pre-post single arm design.
1Treatment groups
Experimental Treatment
Group I: WCM appExperimental Treatment1 Intervention
WCM app evaluation at baseline, upon completion of WCM program and 4 weeks after completion of WCM program, by completing PROMIS and Self Efficacy for managing disease scale questionnaires
Find a Clinic Near You
Research Locations NearbySelect from list below to view details:
University of IllinoisChicago, IL
Loading ...
Who Is Running the Clinical Trial?
University of Illinois at ChicagoLead Sponsor
Northeastern Illinois UniversityCollaborator
Northwestern UniversityCollaborator
References
A systematic review of smartphone applications for cancer survivors. [2023]Mobile phone applications are positioned to support, educate, and empower cancer survivors during post-treatment care. We undertook a review to assess the utility of such smartphone applications; determine whether their use correlates with improved quality of life and other self-reported outcomes; and understand the feasibility of integrating mobile apps into routine follow-up care.
A Smartphone-Based App to Improve Adjuvant Treatment Adherence to Multidisciplinary Decisions in Patients With Early-Stage Breast Cancer: Observational Study. [2021]Multidisciplinary treatment (MDT) and adjuvant therapy are associated with improved survival rates in breast cancer. However, nonadherence to MDT decisions is common in patients. We developed a smartphone-based app that can facilitate the full-course management of patients after surgery.
Feasibility of an eHealth application "OncoKompas" to improve personalized survivorship cancer care. [2022]The purpose of this study was to investigate the feasibility of an online self-management application (OncoKompas) among cancer survivors. In OncoKompas, cancer survivors can monitor their quality of life (QOL) via participant reported outcomes (PROs) ("Measure"), which is followed by automatically generated individually tailored feedback ("Learn") and personalized advice on supportive care services ("Act").
Efficacy, cost-utility and reach of an eHealth self-management application 'Oncokompas' that helps cancer survivors to obtain optimal supportive care: study protocol for a randomised controlled trial. [2018]Cancer survivors have to deal with a wide range of physical symptoms, psychological, social and existential concerns, and lifestyle issues related to cancer and its treatment. Therefore, it is essential that they have access to optimal supportive care services. The eHealth self-management application Oncokompas was developed to support cancer survivors with where they need to turn to for advice and guidance, as well as to increase their knowledge on the availability of optimal support. A randomised controlled trial will be conducted to assess the efficacy, cost-utility and reach of Oncokompas as an eHealth self-management application compared with care as usual among cancer survivors.
Pilot implementation to assess the feasibility and care team impact of an app-based interactive care plan to remotely monitor breast cancer survivors. [2022]To assess the feasibility of an app-based, electronic health record (EHR)-integrated, interactive care plan (ICP) for breast cancer (BC) survivors.
Use of Text Messaging (SMS) for the Management of Side Effects in Cancer Patients Undergoing Chemotherapy Treatment: a Randomized Controlled Trial. [2022]Cancer patients are often not sufficiently oriented to manage side effects at home. Sending text messages with self-care guidelines aimed managing side effects is the main objective of this randomized controlled trial. Patients who started outpatient chemotherapy treatment between March and December 2017 at a hospital in southern Brazil were invited to participate in this study and were allocated to the intervention or control group (ratio 1: 1). Each patient in the intervention group received a daily SMS (short message service) with some guidance on management or prevention of side effects. All text messages were sent to the intervention group patients in an automated and tailored way by our app called cHEmotHErApp. Side effects experienced by patients were verified using the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core-30 (EORTC QLQ-C30). Results showed intervention group patients experienced fewer side effects compared to the control group in cycle 1 (p
Efficacy of an Integrated Mobile Application System for Patients with Radiation Therapy: A Pilot Study. [2022]The use of IT applications for patients undergoing radiotherapy is limited. This study aimed to develop an integrated system for communication between patients and radiation oncologists using IT technology and report the first test results for the system "Assisted Radiation Oncology Mobile Application" (AROMA). This system consisted of a manager program, a server running on a PC, and a mobile application on a smartphone. A prospective survey was conducted to evaluate the usefulness of this system from October 2020 to January 2021. The survey consisted of a specific questionnaire on basic information and application use by the patients. The management program was designed such that the user (doctor) edits the treatment schedule, member (patient and doctor) information, self-management, disease information, and side effect questionnaire. The mobile application for patients consisted of the current schedule, treatment schedule calendar, side effect questionnaire, side effect management method, and disease information entered by the doctor. A total of 41 patients were enrolled in this study. The mean adverse event response time was 4.4 days. In the survey, the mobile application received positive views (8.6/10 points). Most responses related to the side effect reporting function (94%) and communication using the application (91%) were positive. Satisfaction with the application design and each menu item was high, with an average of ≥8 and ≥8.5 points in most cases, respectively. The survey showed good satisfaction with the design, operability, and reporting system. Therefore, the system can facilitate communication between patients and radiation oncologists in the future.
Mobile applications in oncology: A systematic review of health science databases. [2020]In recent years there has been an exponential growth in the number of mobile applications (apps) relating to the early diagnosis of cancer and prevention of side effects during cancer treatment. For health care professionals and users, it can thus be difficult to determine the most appropriate app for given needs and assess the level of scientific evidence supporting their use. Therefore, this review aims to examine the research studies that deal with this issue and determine the characteristics of the apps involved.
Role of eHealth application Oncokompas in supporting self-management of symptoms and health-related quality of life in cancer survivors: a randomised, controlled trial. [2020]Knowledge about the efficacy of behavioural intervention technologies that can be used by cancer survivors independently from a health-care provider is scarce. We aimed to assess the efficacy, reach, and usage of Oncokompas, a web-based eHealth application that supports survivors in self-management by monitoring health-related quality of life (HRQOL) and cancer-generic and tumour-specific symptoms and obtaining tailored feedback with a personalised overview of supportive care options.
Long-term effectiveness of an E-based survivorship care plan for breast cancer survivors: A quasi-experimental study. [2020]The purpose of this study was to evaluate the effect of a web-based survivorship care plan (SCP) computerized application (APP): (SCP-A) on women's unmet needs, fear of recurrence, symptom distress, anxiety, depression, and quality of life (QoL).
Primary care-led survivorship care for patients with colon cancer and the use of eHealth: a qualitative study on perspectives of general practitioners. [2019]The aim of this study was to explore the perspectives of general practitioners (GPs) regarding their current and future role in survivorship care of patients with colon cancer, and to assess their perspectives on patients' self-management capacities and the value of the eHealth application Oncokompas(2.0) used by patients.
[Survivorship care plan (SCP) : The viewpoints of women with breast cancer and their general practitioners]. [2021]The French National Cancer Institute recommends the use of survivorship care plans (SCP) for all cancer survivors. Developing useful SCP's requires understanding of what survivors and their providers need and how SCP's can be implemented in practice. We conducted a study to assess the delivery of SCP comprehensive binders for breast cancer women (BCW) and their general practitioners (GP) in a Cancer center from January 2019.